Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Cervical Muscle Tone Disorders

Fineline Cube Nov 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Drug

Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE

Fineline Cube Nov 28, 2024

Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...

Company Drug

Hansoh Pharmaceutical’s Ameile Receives NMPA Review for Fifth Indication in NSCLC Treatment

Fineline Cube Nov 28, 2024

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing...

Company Drug

China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005

Fineline Cube Nov 28, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...

Company Medical Device

Genesis RMN Robotic Magnetic Navigation System Approved by China’s NMPA

Fineline Cube Nov 28, 2024

The Genesis RMN cardiac electrophysiological robot magnetic navigation system, represented in China by Shanghai Microport...

Company Drug

GSK plc Receives EC Approval for Single-Vial Menveo Vaccine for Meningococcal Disease

Fineline Cube Nov 28, 2024

GSK plc (NYSE: GSK) has announced that it has received marketing approval from the European...

Company Deals

TenNor Therapeutics Partners with Grand Life Sciences for Rifasutenizol Commercialization in China

Fineline Cube Nov 28, 2024

China-based TenNor Therapeutics has entered into an exclusive commercialization cooperation agreement with compatriot firm Grand...

Company Drug

Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA

Fineline Cube Nov 28, 2024

Beijing-based biotech company Immunochina Pharmaceuticals has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment

Fineline Cube Nov 28, 2024

China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National...

Company Drug

Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer

Fineline Cube Nov 28, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced that it has received marketing approval from...

Company

Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore

Fineline Cube Nov 28, 2024

Global healthcare company Sanofi (NASDAQ: SNY) has inaugurated Modulus, its state-of-the-art manufacturing facility in Singapore....

Company Drug

Chia Tai Tianqing’s Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment

Fineline Cube Nov 27, 2024

China-based Chia Tai Tianqing has announced that the National Medical Products Administration (NMPA) has granted...

Company Drug

Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer

Fineline Cube Nov 27, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a China-based biopharmaceutical company, has received market approval...

Policy / Regulatory

NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030

Fineline Cube Nov 27, 2024

The National Healthcare Commission (NHC) has issued the “Guiding Opinions on Further Promoting Mutual Recognition...

Company Drug

CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment

Fineline Cube Nov 27, 2024

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval...

Company Deals

Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments

Fineline Cube Nov 27, 2024

US-based companies Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) and Sarepta Therapeutics (NASDAQ: SRPT) have announced a...

Company Drug

Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China

Fineline Cube Nov 27, 2024

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China...

Legal / IP

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035

Fineline Cube Nov 27, 2024

The China National Intellectual Property Administration (CNIPA) has granted Swiss pharmaceutical giant Roche (SWX: ROG)...

Company Drug

CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing

Fineline Cube Nov 27, 2024

CanSino Biologics (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted...

Company Drug

Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial

Fineline Cube Nov 27, 2024

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...

Posts pagination

1 … 265 266 267 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.